Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Xolair
|
| gptkbp:activities |
Ig E binding inhibition
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:brand |
gptkb:Xolair
|
| gptkbp:clinical_trial |
Phase III
chronic urticaria moderate to severe allergic asthma |
| gptkbp:contraindication |
hypersensitivity to omalizumab
active malignancy severe uncontrolled asthma |
| gptkbp:discovered_by |
gptkb:Genentech
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:education |
importance of adherence to therapy
proper injection technique recognize signs of anaphylaxis reporting side effects |
| https://www.w3.org/2000/01/rdf-schema#label |
omalizumab
|
| gptkbp:indication |
severe asthma
allergic asthma |
| gptkbp:ingredients |
C6480 H10000 N1714 O2000 S44
|
| gptkbp:invention |
gptkb:2023
|
| gptkbp:is_monitored_by |
lung function
symptom control Ig E levels |
| gptkbp:is_used_for |
gptkb:asthma
chronic idiopathic urticaria |
| gptkbp:manager |
subcutaneous
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
half-life of 26 days
decreases allergic response reduces free Ig E levels |
| gptkbp:research_areas |
gptkb:vaccine
allergy treatment asthma treatment |
| gptkbp:side_effect |
fatigue
headache thromboembolic events cardiovascular events injection site reactions anaphylaxis malignancy risk nasopharyngitis |
| gptkbp:targets |
gptkb:Ig_E
|
| gptkbp:weight |
146 k Da
|